Elsevier

Drug and Alcohol Dependence

Volume 164, 1 July 2016, Pages 14-21
Drug and Alcohol Dependence

Full length article
Buprenorphine and methadone treatment for opioid dependence by income, ethnicity and race of neighborhoods in New York City

https://doi.org/10.1016/j.drugalcdep.2016.03.028Get rights and content

Highlights

  • Opioid maintenance treatment unevenly distributed across NYC social areas.

  • Buprenorphine increased in all areas, fastest in highest income, least ethnically diverse area.

  • Methadone treatment usage rates stabilized.

  • Buprenorphine treatment dissemination disparities persist.

Abstract

Background

Geographic and demographic variation in buprenorphine and methadone treatment use in U.S. cities has not been assessed. Identifying variance in opioid maintenance is essential to improving treatment access and equity.

Purpose

To examine the differential uptake of buprenorphine treatment in comparison to methadone treatment between 2004 and 2013 in neighborhoods in New York City characterized by income, race and ethnicity.

Methods

Social area (SA) analysis of residential zip codes of methadone and buprenorphine patients in NYC, which aggregated zip codes into five social areas with similar percentages of residents below poverty, identifying as Black non-Hispanic and as Hispanic, to examine whether treatment rates differed significantly among social areas over time. For each rate, mixed model analyses of variance were run with fixed effects for social area, year and the interaction of social area by year.

Results

Buprenorphine treatment increased in all social areas over time with a significantly higher rate of increase in the social area with the highest income and the lowest percentage of Black, Hispanic, and low-income residents. Methadone treatment decreased slightly in all social areas until 2011 and then increased bringing rates back to 2004 levels. Treatment patterns varied by social area.

Conclusions

Buprenorphine treatment rates are increasing in all social areas, with slower uptake in moderate income mixed ethnicity areas. Methadone rates have remained stable over time. Targeted investments to promote public sector buprenorphine prescription may be necessary to reduce disparities in buprenorphine treatment and to realize its potential as a public health measure.

Introduction

The dramatic rise in the non-medical use of prescription opioids and of heroin in the U.S. over the past decade has had major health consequences: as of 2012, drug overdose became the leading cause of injury death in the U.S., most of these from opioids (Centers for Disease Control and Prevention (CDC, 2014). At the same time, it is estimated that 80% of people dependent on heroin or prescription opioids do not receive treatment (Stancliff et al., 2012). Buprenorphine has emerged as a clinical and public health intervention; a partial opioid agonist, it has comparable effectiveness to methadone in treating heroin and prescription opioid dependence (Mattick et al., 2013). In order to expand access to treatment, in 2002 the U.S. Food and Drug Administration approved the prescription of buprenorphine for opioid maintenance treatment by general physicians in their offices, as an alternative to regulated methadone clinics with directly observed dosing requirements (Wakhlu, 2009).

In Western European countries such as France, buprenorphine provision is seen as a public health measure and promoted by the government among low-income, ethnic minority heroin injecting patients, reducing their HIV and overdose rates (Lovell, 2006, Emmanuelli and Desenclos, 2005). In the U.S., buprenorphine patients have historically been privately insured prescription opioid users. As of 2005, buprenorphine patients were likely to be White (92% compared to 53% of methadone patients), employed (56% vs 29% of methadone patients), to have some college education (56% vs 19% of methadone patients), and to be prescription opioid dependent (75%) rather than heroin dependent (Stanton et al., 2006). Although no nationally representative data on the socioeconomic status or ethnicity/race of buprenorphine patients has been published since the Stanton et al. study, recent city and state-level analysis have found similar racial and socioeconomic trends (Hansen et al., 2013, Stein et al., 2015a, Stein et al., 2015b),

The demographic patterns of buprenorphine treatment in the U.S. may be explained by Congress’ desire to address the growth in suburban and rural prescription opioid and heroin use, which was enhanced by targeted marketing of new prescription opioids in those areas beginning in the 1990s (Zee, 2009). Members of Congress passed legislation enabling office-based buprenorphine maintenance that would be more palatable to a growing population of suburban, opioid dependent people than methadone clinics (Egan et al., 2010). Additionally, the manufacturer advertised to consumers primarily over the internet, and helped the Substance Abuse and Mental Health Services Administration launch a web-based physician locator to help patients find buprenorphine certified prescribers (Hansen and Roberts, 2012), which may have favored literate and more affluent consumers. The certification requirement for eight hours of training itself contributed to a shortage of public sector buprenorphine prescribers (Barry et al., 2009).

Heroin and other opioid use remains an endemic cause of overdose death, HIV and hepatitis C infection among Blacks and Hispanics (CDC African Americans, 2015; CDC Latinos, 2015; CDC Health Disparities, 2015; Khlifi et al., 2009, Mack, 2013). Buprenorphine has been shown to improve treatment retention and health outcomes among low-income, socially marginalized populations (Hersh et al., 2011, Stancliff et al., 2012) including formerly incarcerated patients (Lee et al., 2012, Magura et al., 2009) who often express a preference for buprenorphine over methadone (Mitchell et al., 2012). Disparities in access to buprenorphine represent a missed opportunity to protect the health of these populations.

To address the uneven distribution of buprenorphine, all states now include some form of Medicaid coverage for buprenorphine (Rinaldo and Rinaldo, 2013), and certain major cities, including Baltimore and Boston, actively promote buprenorphine treatment in public clinics (Schwartz et al., 2013, Hersh et al., 2011). Beginning in 2005, New York City’s public hospitals publicized buprenorphine among patients, encouraged physicians to become certified, and offered buprenorphine in outpatient and inpatient settings (personal communication with Peter Coleman, M.D., June 24, 2013). New York City is instructive with regard to buprenorphine access; while it has the greatest number of opioid dependent residents of any U.S. city, with estimates ranging from 92,000 to 200,000 (Frank, 2000), only an estimated 11–23% have initiated treatment (McNeely et al., 2012). Their untreated opioid dependence has significant consequences; injection drug use is a primary reason that New York has the highest number of new HIV cases in the U.S. (Centers for Disease Control and Prevention (CDC, 2012).

Despite New York City’s promotion of buprenorphine in public clinics, as of 2007, buprenorphine patients were significantly more likely to live in high income, predominantly White areas of New York City, while methadone patients were significantly more likely to live in low-income, predominantly Black or Hispanic areas (Hansen et al., 2013). The question raised in this paper is whether these treatment patterns persist. Theories of the health impact of new health technologies in socially stratified societies predict that they increase disparities in health and health care, due to uptake among consumers that have the economic, cultural and social capital to access them. In the absence of countervailing public investments, new technologies are used by more affluent, educated patients, and the use of these technologies further increases disparities in disease detection, treatment access, and mortality based on education and income (Glied and Lleras-Muney, 2008, Tehranifar et al., 2009). This compounds pre-existing health inequalities: Link and Phelan (1995) have argued that socioeconomic inequalities fundamentally cause health disparities by putting people “at risk of risk”.

This study traces geographic changes in buprenorphine maintenance treatment (BMT) and methadone maintenance treatment (MMT) across neighborhoods with markedly different demographics and income levels, over a period of regulatory changes and increases in opioid use. In 2007, a Federal amendment raised the legal limit of buprenorphine patients per provider from 30 to 100. In 2012, a Federal regulatory change allowed methadone clinics to dispense take-home buprenorphine. By 2013, New York City reported an unprecedented rise in opioid overdose deaths (Siegler et al., 2014). In analyses in which usage rates of buprenorphine and of methadone are the dependent variables and usage is examined over constructed social areas defined by their income levels and ethnic mix, the hypotheses tested were: 1) usage of methadone has declined and of buprenorphine has increased in all social areas; 2) the variation among neighborhoods defined by income, race/ethnicity in buprenorphine and methadone usage persists over time.

Section snippets

Data

The buprenorphine treatment rate was determined from data collected by the Federal Drug Enforcement Agency (DEA) on the number of buprenorphine prescriptions written from 2004 to 2013 by residential postal ZIP code of the patient treated. Data were supplied by the New York State Bureau of Narcotics Enforcement. Although independent verification of the completeness of this data is not available, it is the most complete publicly available data set on buprenorphine prescriptions because retail

Social area analyses

The five social areas identified were characterized by their mean percent of having a demographic characteristic that by using cluster analysis had been classified into low (L), medium (M), or high (H) mean percent of the characteristic. Cut-points for percent in poverty were L < 34% and for H > 47%; L and H cut-points for Black, non-Hispanic 19% and 51% and for Hispanic 31% and 53%. SD denotes standard deviations (See Table 1).

Unadjusted means

Fig. 1, Fig. 2 plot the unadjusted means of the BMT and MMT rates

Discussion

Over time, there was a steady growth in buprenorphine treatment rates in all New York City social areas (SAs) studied. This is consistent with national studies showing that the number of buprenorphine prescriptions per capita has increased overall (Stein et al., 2015a, Stein et al., 2015b). Methadone rates modestly declined until 2011, but by 2013 had returned to 2004 levels. In 2013, in the high income, predominately white SA 1, the buprenorphine treatment rate was high in contrast to a low

Role of funding source

This work was supported by NIHDA032674 (to the first author), and by the Robert Wood Johnson Health Policy Investigator Award Program (to the first author). Additional support was granted by the Nathan Kline Institute's Center of Excellence in Culturally Competent Mental Health, funded by the New York State Office of Mental Health.

Contributors

Helena Hansen conceived the paper idea and led the writing of the paper. Carole Siegel designed the quantitative approach and led the statistical analysis. Joseph Wanderling and Danae DiRocco analyzed and interpreted data as well as assisted with writing and revising the paper.

Conflict of interest

The authors have no conflicts of interest to declare.

Acknowledgements

We gratefully acknowledge the assistance of Dawn Lambert-Wacey of the New York State Office of Alcoholism and Substance Abuse for her help accessing the methadone usage data for this study, as well as the New York State Bureau of Narcotics for assistance in accessing buprenorphine usage data. Thanks also to the thoughtful feedback of three anonymous reviewers, and to Sonia Mendoza and Jennifer Hernandez for copy editing. This study was supported by NIH award DA032674-05 (to Hansen), the Robert

References (55)

  • Centers for Disease Control (CDC)

    CDC Fact Sheet: HIV among African Americans

    (2015)
  • Centers for Disease Control (CDC)

    CDC Fact Sheet: HIV among Latinos.

    (2015)
  • Centers for Disease Control (CDC)

    Health Disparities in HIV/AIDS, Viral Hepatitis, STDs, and TB.

    (2015)
  • Centers for Disease Control and Prevention (CDC), 2012. Estimated HIV incidence in the United States, 2007–2010. HIV...
  • Centers for Disease Control and Prevention (CDC)

    Prescription Drug Overdose in the United States: Fact Sheet.

    (2014)
  • K.L. Chau

    Ecological analysis of health care utilization for China’s rural population: association with a rural county’s socioeconomic characteristics

    BMC Public Health

    (2010)
  • C.O. Cunningham et al.

    Attending physicians’ and residents’ attitudes and beliefs about prescribing buprenorphine at an urban teaching hospital

    Fam. Med.

    (2006)
  • C. Cunningham et al.

    Buprenorphine treatment in an urban community health center: what to expect

    Fam. Med.

    (2008)
  • J. Das-Munshi et al.

    Understanding the effect of ethnic density on mental health: multi-level investigation of survey data from England

    BMJ

    (2010)
  • L.J. Ducharme et al.

    State policy influence on the early diffusion of buprenorphine in community treatment programs

    Subst. Abuse Treat. Prev. Policy

    (2008)
  • J.E. Egan et al.

    The Physician Clinical Support System-Buprenorphine (PCSS-B): a novel project to expand/improve buprenorphine treatment

    J. Gen. Intern. Med.

    (2010)
  • J. Emmanuelli et al.

    Harm reduction interventions, behaviours and associated health outcomes in France, 1996–2003

    Addiction

    (2005)
  • B. Frank

    2000. An overview of heroin trends in New York City: past, present and future

    Mt. Sinai J. Med.

    (2000)
  • S. Glied et al.

    Technological innovation and inequality in health

    Demography

    (2008)
  • D.C. Gottfredson et al.

    Social area influences on delinquency: a multilevel analysis

    J. Res. Crime Delinq.

    (1991)
  • T.H. Grubesic et al.

    On the use of ZIP codes and ZIP code tabulation areas (ZCTAs) for the spatial analysis of epidemiological data

    Int. J. Health Geogr. Dec.

    (2006)
  • H. Hansen et al.

    Two tiers of biomedicalization: buprenorphine: methadone and the biopolitics of addiction stigma and race

    Adv. Med. Soc.

    (2012)
  • Cited by (0)

    View full text